CA2888722C - Inhibition de la phosphorylation de pras40, gsk3-beta ou p70s6k1 en tant que marqueur de l'activite inhibitrice de la kinase tor - Google Patents
Inhibition de la phosphorylation de pras40, gsk3-beta ou p70s6k1 en tant que marqueur de l'activite inhibitrice de la kinase tor Download PDFInfo
- Publication number
- CA2888722C CA2888722C CA2888722A CA2888722A CA2888722C CA 2888722 C CA2888722 C CA 2888722C CA 2888722 A CA2888722 A CA 2888722A CA 2888722 A CA2888722 A CA 2888722A CA 2888722 C CA2888722 C CA 2888722C
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- pyrazin
- unsubstituted
- tor kinase
- dihydropyrazino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des méthodes de traitement d'un cancer par inhibition de la phosphorylation de PRAS40, GSK3ß ou p70S6Kl, qui consistent à administrer une quantité efficace d'un inhibiteur de la kinase TOR à un patient atteint d'un cancer pouvant être traité par inhibition de la phosphorylation de PRAS40, GSK3ß ou p70S6K1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261715542P | 2012-10-18 | 2012-10-18 | |
US61/715,542 | 2012-10-18 | ||
PCT/US2013/065364 WO2014066125A2 (fr) | 2012-10-18 | 2013-10-17 | Inhibition de la phosphorylation de pras40, gsk3-beta ou p70s6k1 en tant que marqueur de l'activité inhibitrice de la kinase tor |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2888722A1 CA2888722A1 (fr) | 2014-05-01 |
CA2888722C true CA2888722C (fr) | 2023-02-21 |
Family
ID=50001239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2888722A Active CA2888722C (fr) | 2012-10-18 | 2013-10-17 | Inhibition de la phosphorylation de pras40, gsk3-beta ou p70s6k1 en tant que marqueur de l'activite inhibitrice de la kinase tor |
Country Status (11)
Country | Link |
---|---|
US (2) | US9155736B2 (fr) |
EP (1) | EP2909627B1 (fr) |
JP (1) | JP2015536450A (fr) |
CN (2) | CN104870998B (fr) |
AU (1) | AU2013203714B2 (fr) |
CA (1) | CA2888722C (fr) |
ES (1) | ES2669269T3 (fr) |
HK (1) | HK1213049A1 (fr) |
MX (1) | MX2015004875A (fr) |
NZ (1) | NZ630416A (fr) |
WO (1) | WO2014066125A2 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105188704B (zh) | 2013-01-16 | 2017-09-19 | 西格诺药品有限公司 | 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法 |
US9359364B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one |
TWI656875B (zh) | 2013-04-17 | 2019-04-21 | 美商標誌製藥公司 | 藉二氫吡并吡治療癌症 |
EP2986322A1 (fr) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Polythérapie comprenant un inhibiteur de kinase tor et un composé de quinazolinone substitué en 5 pour le traitement du cancer |
CN105377299B (zh) | 2013-04-17 | 2018-06-12 | 西格诺药品有限公司 | 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法 |
EA030808B1 (ru) | 2013-04-17 | 2018-09-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ |
NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
WO2015160868A1 (fr) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | Méthodes de traitement du cancer à l'aide d'une polythérapie avec des inhibiteurs de la kinase tor |
WO2015160880A1 (fr) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières |
US9623028B2 (en) | 2014-07-14 | 2017-04-18 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
SG11201912403SA (en) | 2017-06-22 | 2020-01-30 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
WO2021204109A1 (fr) * | 2020-04-06 | 2021-10-14 | The University Of Hong Kong | Utilisation de la p70 s6 kinase nucléaire pour le diagnostic, le pronostic et le traitement du cancer |
CN111910005B (zh) * | 2020-08-19 | 2021-09-24 | 中国医学科学院肿瘤医院 | Cdk4/6抑制剂敏感性相关基因及其应用 |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
US3567725A (en) | 1968-11-20 | 1971-03-02 | Merck & Co Inc | Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones |
US4294837A (en) | 1980-03-28 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use |
US4294836A (en) | 1980-03-24 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use |
US4317909A (en) | 1980-03-24 | 1982-03-02 | Sterling Drug Inc. | Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones |
US4309537A (en) | 1980-03-28 | 1982-01-05 | Sterling Drug Inc. | Production of imidazo[4,5-b]pyridin-2-ones or thiones |
GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
JPS63275582A (ja) | 1987-05-02 | 1988-11-14 | Naade Kenkyusho:Kk | 2−アミノイミダゾ〔4,5−b〕ピリジン誘導体の製造方法 |
DD262026A1 (de) | 1987-07-10 | 1988-11-16 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen |
FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
TW274550B (fr) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
DE19601627A1 (de) | 1996-01-18 | 1997-07-24 | Bayer Ag | Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone |
US6031105A (en) | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
CA2305370C (fr) | 1997-09-26 | 2006-11-28 | Gerald Mcmahon | Composes a base d'azabenzimidazole destines a la modulation d'une fonction de proteine kinase de serine/threonine |
CA2311414A1 (fr) | 1997-11-27 | 1999-06-10 | Chugai Research Institute For Molecular Medicine, Inc. | Technique de diagnostique, reactif pour diagnostique et preparation therapeutique pour les maladies provoquees par des modifications survenues dans le gene lkb1 |
ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
EP1186232A4 (fr) | 1999-05-31 | 2004-11-10 | Chugai Pharmaceutical Co Ltd | Animaux rompant le gene lkb1 |
JP2003146987A (ja) | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | 2−アリールプリン−9−アセトアミド誘導体 |
JP3814125B2 (ja) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | 2−アリール−8−オキソジヒドロプリン誘導体からなる医薬 |
JP2002100363A (ja) | 2000-09-25 | 2002-04-05 | Mitsubishi Chemicals Corp | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
JP2002167387A (ja) | 2000-11-29 | 2002-06-11 | Dainippon Pharmaceut Co Ltd | 2−(7,8−ジヒドロ−8−オキソ−9h−プリン−9−イル)酢酸誘導体 |
US6566367B2 (en) | 2000-12-12 | 2003-05-20 | Pfizer Inc. | Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines |
WO2002076954A1 (fr) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferantes |
DE50207522D1 (de) | 2001-09-04 | 2006-08-24 | Boehringer Ingelheim Int | Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
JP2005506350A (ja) | 2001-10-18 | 2005-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物 |
TWI314928B (en) | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
AU2003299531A1 (en) | 2002-08-05 | 2004-06-07 | University Of Massachusetts | Compounds for modulating rna interference |
CA2502429A1 (fr) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Agents anti-inflammatoires |
MXPA05005477A (es) | 2002-11-21 | 2005-07-25 | Chiron Corp | Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer. |
CA2512646A1 (fr) | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | Heterocycles 2-aminopyridines substitues utilises comme inhibiteurs de la proliferation cellulaire |
AU2003215591B2 (en) | 2003-02-26 | 2010-06-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Dihydropteridinones, method for the production and use thereof in the form of drugs |
GB0305152D0 (en) | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
PT3521297T (pt) | 2003-05-30 | 2022-03-18 | Gilead Pharmasset Llc | Análogos de nucleosídeo fluorados modificados |
AU2004263080B2 (en) | 2003-06-26 | 2008-12-18 | Merck Sharp & Dohme Corp. | Benzodiazepine CGRP receptor antagonists |
ES2308198T3 (es) | 2003-07-17 | 2008-12-01 | University Of Dundee | Metodos para el uso de un complejo lkb1/strad/mo25. |
GB0320197D0 (en) | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
US20080194019A1 (en) | 2003-09-09 | 2008-08-14 | Beth Israel Deaconess Medical Center, Inc. | Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase |
CN101123968A (zh) | 2004-06-04 | 2008-02-13 | 艾科斯有限公司 | 肥大细胞病的治疗方法 |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
WO2006001266A1 (fr) | 2004-06-23 | 2006-01-05 | Banyu Pharmaceutical Co., Ltd. | Procédé permettant de produire un dérivé de 2-arylpurine |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
CN101065016A (zh) | 2004-09-24 | 2007-10-31 | 詹森药业有限公司 | 蛋白激酶的抑制剂咪唑并[4,5-b]吡嗪酮 |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
WO2006050076A1 (fr) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Composes de pyrrolyle fusionnes substitues par pyrimidinyle et utiles dans le traitement des troubles induits par la kinase |
JP5118972B2 (ja) | 2004-10-29 | 2013-01-16 | テイボテク・フアーマシユーチカルズ | Hiv阻害性二環式ピリミジン誘導体 |
SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | Biovitrum Ab | New compounds |
JP5111113B2 (ja) | 2004-12-13 | 2012-12-26 | サネシス ファーマシューティカルズ, インコーポレイテッド | Rafキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン |
BRPI0607455A2 (pt) | 2005-02-16 | 2009-09-01 | Astrazeneca Ab | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica |
WO2006091737A1 (fr) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulateurs de l'activite de gsk-3 |
KR20070113252A (ko) | 2005-02-25 | 2007-11-28 | 쿠도스 파마슈티칼스 리미티드 | 2,4-디아미노-피리도피리미딘 유도체 및 이의 mTOR억제제로서의 용도 |
JP2008531537A (ja) | 2005-02-25 | 2008-08-14 | クドス ファーマシューティカルズ リミテッド | 化合物 |
MX2007012393A (es) | 2005-04-05 | 2008-02-22 | Pharmacopeia Inc | Derivados de purina e imidazopiridina para la inmunosupresion. |
AU2006302179C1 (en) | 2005-10-07 | 2013-06-20 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
JP5461012B2 (ja) | 2005-10-07 | 2014-04-02 | エクセリクシス, インク. | PI3Kαのピリドピリミジノン型阻害剤 |
WO2007044698A1 (fr) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | INHIBITEURS PYRIDOPYRIMIDINONE DE PI3Kα |
CN101421625A (zh) * | 2005-10-18 | 2009-04-29 | 乔治梅森知识产权公司 | mTOR途径治疗诊断学 |
ATE507227T1 (de) | 2005-11-17 | 2011-05-15 | Osi Pharm Inc | Kondensierte bicyclische mtor-inhibitoren |
WO2007060404A1 (fr) | 2005-11-22 | 2007-05-31 | Kudos Pharmaceuticals Limited | Dérivés de pyrido-, pyrazo- et pyrimido-pyrimidine en tant qu'inhibiteurs de mtor |
GB0525083D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525080D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
EP1979325A1 (fr) | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Dérivés de morpholinopyrimidine et leur utilisation thérapeutique |
US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
ES2878130T3 (es) | 2006-04-25 | 2021-11-18 | Astex Therapeutics Ltd | Derivados de purina y deazapurina como compuestos farmacéuticos |
ES2347187T3 (es) | 2006-04-26 | 2010-10-26 | F. Hoffmann-La Roche Ag | Derivado de tieno(3,2-d)pirimidina, util como un inhibidor de pi3k. |
WO2007129044A1 (fr) | 2006-05-03 | 2007-11-15 | Astrazeneca Ab | Dérivés de thiazole et leur utilisation comme agents anti-tumoraux |
US20090118336A1 (en) | 2006-05-03 | 2009-05-07 | Laurent David | Pyrazole derivatives and their use as pi3k inhibitors |
CN101448827A (zh) | 2006-05-22 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 吲哚衍生物 |
RS54542B1 (en) | 2006-08-02 | 2016-06-30 | Cytokinetics, Inc. | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INCLUDING IMIDAZOPYRIMIDINE |
WO2008023161A1 (fr) | 2006-08-23 | 2008-02-28 | Kudos Pharmaceuticals Limited | Dérivés de la 2-méthylmorpholine pyrido-, pyrazo- et pyrimido-pyrimidine en tant qu'inhibiteurs de mtor |
EP2364702A3 (fr) | 2006-09-05 | 2012-01-25 | Emory University | Inhibiteurs de kinase pour la prévention ou le traitement d'une infection |
WO2008030744A2 (fr) | 2006-09-05 | 2008-03-13 | Board Of Regents, The University Of Texas System | Inhibiteurs de c-met et leurs utilisations |
JP2010503648A (ja) | 2006-09-14 | 2010-02-04 | アストラゼネカ アクチボラグ | 増殖性疾患の治療のためのpi3k及びmtor阻害剤としての2−ベンゾイミダゾリル−6−モルホリノ−4−(アゼチジン、ピロリジン、ピペリジン、又はアゼピン)ピリミジン誘導体 |
WO2008032027A1 (fr) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Dérivés de pyrimidine |
WO2008032036A1 (fr) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Dérivés de 6-benzimidazolyl-2-morpholino-4-(azétidine, pyrrolidine, piperidine ou azépine) pyrimidine comme inhibiteurs de pi3k et mtor pour le traitement de troubles prolifératifs |
JP2010503649A (ja) | 2006-09-14 | 2010-02-04 | アストラゼネカ アクチボラグ | ピリミジン誘導体 |
WO2008032033A1 (fr) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Dérivés de 4-benzimidazolyl-2-morpholino-6-pipérazinylpyrimidine utilisés en tant que pi3k et inhibiteurs de mtor destinés au traitement de troubles prolifératifs |
CN101563340A (zh) | 2006-09-14 | 2009-10-21 | 阿斯利康(瑞典)有限公司 | 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物 |
WO2008032077A1 (fr) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Dérivés de pyrimidine |
WO2008032091A1 (fr) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Dérivés de pyrimidine |
WO2008032089A1 (fr) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Dérivés de 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine utilisés comme inhibiteurs de p13k et de mtor pour le traitement de troubles prolifératifs |
WO2008032060A1 (fr) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Dérivés de 4-benzimidaz0lyl-6-m0rph0lin0-2-pipérazinylpyrimidine utilisés comme inhibiteurs de p13k et mtor dans le traitement de troubles prolifératifs |
CL2007002866A1 (es) | 2006-10-04 | 2008-07-04 | Pharmacopeia Inc | Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m |
US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
ES2383370T3 (es) | 2006-10-19 | 2012-06-20 | Signal Pharmaceuticals Llc | Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa |
EP2090577B1 (fr) | 2006-10-19 | 2017-04-05 | Signal Pharmaceuticals, LLC | Composés héteroaryliques, compositions les contenant et leur utilisation en tant qu'inhibiteurs de protein kinases |
US8436177B2 (en) | 2006-11-20 | 2013-05-07 | Novartis Ag | Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
JP2010533158A (ja) | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物類−945 |
AU2008273891B2 (en) | 2007-07-09 | 2012-01-12 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K |
JP2010533161A (ja) | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物−946 |
CA2702838A1 (fr) | 2007-10-16 | 2009-04-23 | Wyeth Llc | Composes thienopyrimidine et pyrazolopyrimidine et leur utilisation en tant que des inhibiteurs de la kinase mtor et de la kinase pi3 |
US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
MX2010007746A (es) | 2008-01-15 | 2010-08-18 | Wyeth Llc | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de diana de rapamicina de mamifero quinasa y fosfatidilinositol quinasa y su sintesis. |
WO2009102986A1 (fr) | 2008-02-15 | 2009-08-20 | Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) | Traitement de l'adénocarcinome exprimant lkb1 avec l'inhibiteur mtor en combinaison avec l'inhibiteur cox1 |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
PL2477987T3 (pl) | 2009-09-14 | 2018-06-29 | Gilead Sciences, Inc. | Modulatory receptorów toll-podobnych |
MX341704B (es) | 2009-10-26 | 2016-08-31 | Signal Pharm Llc | Métodos de síntesis y purificación de compuestos de heteroarilo. |
AU2010336509A1 (en) | 2009-12-23 | 2012-07-19 | Elan Pharmaceuticals, Inc | Pteridinones as inhibitors of polo-like kinase |
WO2011097333A1 (fr) | 2010-02-03 | 2011-08-11 | Signal Pharmaceuticals, Llc | Identification d'une mutation lkb1 comme biomarqueur de prédiction de sensibilité à des inhibiteurs de kinase tor |
US20110318336A1 (en) | 2010-03-29 | 2011-12-29 | George Mason Intellectual Properties, Inc. | Identification and Treatment of Aggressive Lung Cancer Tumors |
US20120028972A1 (en) * | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
MX2014001246A (es) | 2011-08-03 | 2014-06-11 | Signal Pharm Llc | Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1. |
TWI758746B (zh) | 2011-10-19 | 2022-03-21 | 美商標誌製藥公司 | 以tor激酶抑制劑治療癌症 |
EA026390B1 (ru) | 2011-12-02 | 2017-04-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ 7-(6-(2-ГИДРОКСИПРОПАН-2-ИЛ)ПИРИДИН-3-ИЛ)-1-((ТРАНС)-4-МЕТОКСИЦИКЛОГЕКСИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА, ИХ ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
ES2742398T3 (es) | 2012-02-24 | 2020-02-14 | Signal Pharm Llc | Métodos para tratar el cáncer de pulmón no microcítico usando una terapia de combinación de inhibidores de TOR quinasa |
ES2677874T3 (es) | 2012-03-15 | 2018-08-07 | Signal Pharmaceuticals, Llc | Tratamiento del cáncer con inhibidores de la cinasa TOR |
CN104271139A (zh) | 2012-03-15 | 2015-01-07 | 西格诺药品有限公司 | 用tor激酶抑制剂治疗癌症 |
WO2013138560A1 (fr) | 2012-03-15 | 2013-09-19 | Signal Pharmaceuticals, Llc | Traitement du cancer avec des inhibiteurs de la kinase tor |
MX360877B (es) | 2012-03-15 | 2018-11-21 | Signal Pharm Llc | Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il) -3,4-dihidropirazino[2,3-b]pirazin-(1h)-ona para usarse en el tratamiento de sarcoma de ewing que sobreexpresa e-veintiseis(ets). |
AU2013202768B2 (en) | 2012-10-18 | 2015-11-05 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
-
2013
- 2013-04-11 AU AU2013203714A patent/AU2013203714B2/en active Active
- 2013-10-17 ES ES13824222.7T patent/ES2669269T3/es active Active
- 2013-10-17 EP EP13824222.7A patent/EP2909627B1/fr active Active
- 2013-10-17 CN CN201380066368.1A patent/CN104870998B/zh active Active
- 2013-10-17 CA CA2888722A patent/CA2888722C/fr active Active
- 2013-10-17 NZ NZ630416A patent/NZ630416A/en unknown
- 2013-10-17 US US14/055,995 patent/US9155736B2/en active Active
- 2013-10-17 MX MX2015004875A patent/MX2015004875A/es unknown
- 2013-10-17 JP JP2015537810A patent/JP2015536450A/ja active Pending
- 2013-10-17 WO PCT/US2013/065364 patent/WO2014066125A2/fr active Application Filing
- 2013-10-17 CN CN201711337532.4A patent/CN107976546B/zh active Active
-
2015
- 2015-08-26 US US14/835,817 patent/US9557338B2/en active Active
-
2016
- 2016-01-25 HK HK16100807.5A patent/HK1213049A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
NZ630416A (en) | 2016-12-23 |
HK1213049A1 (zh) | 2016-06-24 |
EP2909627A2 (fr) | 2015-08-26 |
CN107976546A (zh) | 2018-05-01 |
AU2013203714A1 (en) | 2014-05-08 |
US20150362505A1 (en) | 2015-12-17 |
ES2669269T3 (es) | 2018-05-24 |
JP2015536450A (ja) | 2015-12-21 |
CA2888722A1 (fr) | 2014-05-01 |
WO2014066125A3 (fr) | 2014-08-07 |
US9155736B2 (en) | 2015-10-13 |
MX2015004875A (es) | 2015-08-05 |
US20140113905A1 (en) | 2014-04-24 |
CN104870998B (zh) | 2018-02-02 |
AU2013203714B2 (en) | 2015-12-03 |
US9557338B2 (en) | 2017-01-31 |
CN107976546B (zh) | 2020-10-27 |
CN104870998A (zh) | 2015-08-26 |
EP2909627B1 (fr) | 2018-04-04 |
WO2014066125A2 (fr) | 2014-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2888722C (fr) | Inhibition de la phosphorylation de pras40, gsk3-beta ou p70s6k1 en tant que marqueur de l'activite inhibitrice de la kinase tor | |
CA2788678C (fr) | Identification d'une mutation lkb1 comme biomarqueur de prediction de sensibilite a des inhibiteurs de kinase tor | |
CA2867174C (fr) | Traitement du cancer avec des inhibiteurs de la kinase tor | |
EP2825168B1 (fr) | Traitement du cancer avec des inhibiteurs de la kinase tor | |
AU2013203153A1 (en) | Treatment of cancer with TOR kinase inhibitors | |
KR102157914B1 (ko) | Tor 키나제 억제제를 사용한 전립선암의 치료 | |
AU2015213397B2 (en) | Treatment of cancer with TOR kinase inhibitors | |
AU2015213400B2 (en) | Treatment of cancer with TOR kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20181011 |
|
EEER | Examination request |
Effective date: 20181011 |
|
EEER | Examination request |
Effective date: 20181011 |
|
EEER | Examination request |
Effective date: 20181011 |
|
EEER | Examination request |
Effective date: 20181011 |
|
EEER | Examination request |
Effective date: 20181011 |